Journal for ImmunoTherapy of Cancer (Nov 2023)
926 BAY 2965501: a highly selective DGK zeta inhibitor for cancer immunotherapy
- Rienk Offringa,
- Catherine Olesch,
- Frederik Cichon,
- Mareike Grees,
- Norbert Schmees,
- Ulrike Roehn,
- Florian Prinz,
- Detlef Stoeckigt,
- Michael Erkelenz,
- Thi Thanh Uyen Nguyen,
- Ulf Boemer,
- Judith Günther,
- Marc Kunze,
- Kirstin Petersen,
- Dennis Kirchhoff
Affiliations
- Rienk Offringa
- Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Baden-Württemberg, Germany
- Catherine Olesch
- 1German Cancer Research Center (DKFZ), Heidelberg, Germany
- Frederik Cichon
- 1German Cancer Research Center (DKFZ), Heidelberg, Germany
- Mareike Grees
- 2Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany
- Norbert Schmees
- 3NUVISAN ICB GmbH, Berlin, Germany
- Ulrike Roehn
- 3NUVISAN ICB GmbH, Berlin, Germany
- Florian Prinz
- 3NUVISAN ICB GmbH, Berlin, Germany
- Detlef Stoeckigt
- 3NUVISAN ICB GmbH, Berlin, Germany
- Michael Erkelenz
- 3NUVISAN ICB GmbH, Berlin, Germany
- Thi Thanh Uyen Nguyen
- 3NUVISAN ICB GmbH, Berlin, Germany
- Ulf Boemer
- 3NUVISAN ICB GmbH, Berlin, Germany
- Judith Günther
- 2Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany
- Marc Kunze
- 2Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany
- Kirstin Petersen
- 2Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany
- Dennis Kirchhoff
- 2Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany
- DOI
- https://doi.org/10.1136/jitc-2023-SITC2023.0926
- Journal volume & issue
-
Vol. 11,
no. Suppl 1
Abstract
No abstracts available.
